The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2024 | Clinical targeting of adaptive resistance in colorectal cancer
Scott Kopetz, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, highlights the clinical implications of targeting adaptive resistance in BRAF- and KRAS-mutated colorectal cancer. Targeting adaptive resistance is already the standard of care for BRAF V600E-mutated colorectal cancer, through the use of encorafenib and cetuximab. Following the results of the Phase I/II KRYSTAL-1 trial (NCT03785249) of adagrasib and cetuximab in BRAF- and KRAS-mutated colorectal cancer, there are anticipated changes to the National Comprehensive Cancer Network (NCCN) guidelines for treatment and approval by the FDA. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
